A retrospective mortality analysis and prospective morbidity and haematological analyses were performed for Shell Deer Park Manufacturing Complex (DPMC) male employees who worked in jobs with potential exposure to 1,3-butadiene from 1948 to 1989. 614 employees qualified for the mortality study , 438 of those were still employed during the period of the morbidity study , and 429 of those had haematological data available for analysis. Industrial hygiene data from 1979 to 1992 showed that most butadiene exposures did not exceed 10 ppm (eighthour time weighted average (8 hour TWA)), and most were below 1 ppm, with an arithmetic mean of 3-5 ppm. 24 deaths occurred during the mortality study period. For all causes of death, the standardised mortality ratio (SMR) was 48 (95% confidence interval (95% CI) = 31-72), and the all cancer SMR was 34 (95% CI = 9-87). There were only two deaths due to lung cancer (SMR 42, 95% CI = 5-151) and none due to lymphohaematopoietic cancer (expected = 1.2).
haematopoietic cancer (expected = 1.2).
Morbidity (illness absence) events of six days or more for the 438 butadiene employees were compared with the rest of the complex. No cause of morbidity was in excess for this group; the all cause standardised morbidity ratio (SMbR) was 85 (95% CI = 77-93) and the all neoplasms SMbR was 51 (95% CI = 22-100). Haematological results for the 429 with laboratory data were compared with results for the rest of the complex. No significant differences occurred between the two groups and the distributions of results between butadiene and non-butadiene groups were virtually identical.
These results suggest that butadiene exposures at concentrations common at DPMC in the past 10-20 years do not pose a health hazard to employees. ( 18 October 1993 Shell Oil Company is a producer of 1,3-butadiene monomer (butadiene) that is sold to rubber industry producers who combine it with styrene to manufacture styrene-butadiene rubber, the rubber used for car and lorry tyres, among other products. As a producer of butadiene, Shell has an interest in potential butadiene toxicity both from the standpoint of employee and customer safety. Shell began producing butadiene in 1941 at the Shell Deer Park Refinery (later to become the Deer Park Manufacturing Complex (DPMC)). During the second world war, DPMC supplied up to one third of the nation's butadiene.l Production of butadiene ceased in 1948 and was not resumed at Deer Park until 1970. Since 1970, the Deer Park facility has produced butadiene monomer without interruption.
Because of interest in the possible carcinogenicity of butadiene and because Shell is in the midst of an update of a mortality study of the entire DPMC originally conducted by Marsh et al,2 we have been able to identify and evaluate the health experience of a cohort of employees with long term potential exposure to butadiene. Because many of these employees are still employed by Shell, it has been possible to examine not only their mortality, but also their morbidity (illness absence) and results of medical examinations. This report is divided into three parts. The first describes a retrospective mortality study of 614 employees from 1948 to 1989. The second is an examination of the morbidity experience from 1982 to 1991 for those (n = 438) still working during the period 1982 to 1989. The third is an evaluation of the haematological results from routine medical examination of employees (n = 429) with potential exposure to butadiene. Excesses and deficits of morbidity are expressed as standardised morbidity ratios (SMbRs) that were computed as the ratio of the observed to the expected morbidity events for each cause of interest. The expected numbers of morbidity events were calculated from the age, pay state (hourly or salaried), and cause specific morbidity of the internal comparison group. Tests of statistical significance were based on the assumption that the observed number of morbidity events follows a Poisson distribution. 6 Selected health risk factors including smoking, raised blood pressure, raised cholesterol, and obesity were also examined to evaluate the differences in health habits between the butadiene group and the internal comparison group. The employee's smoking history was used to determine whether the employee was a current cigarette smoker. Raised cholesterol was defined as a value equal to or greater than 200 mg/dl (5 18 mmol/l). Raised blood pressures were those diastolic blood pressure readings equal to or greater than 90 mm Hg (11-97 kPa) or systolic blood pressure readings equal to or greater than 140 mm Hg (18-62 kPa). Obesity was defined as body mass index (BMI = weight (kg)/height(m)2) greater than or equal to 27'2. This value represents 20% more than ideal body weight.
Materials and methods
PART III: HAEMATOLOGICAL DATA EVALUATION Four hundred and twenty nine of the 438 employees included in the morbidity study had haematological data from periodic physical examinations provided by the company. The most current laboratory test results were used and compared with similar results for over 2600 non-exposed DPMC employees. About 80% of these tests were done between 1985 and 1991. Seven haematological outcomes including red cell count (106/mm3), haemoglobin concentration (g/100 ml), mean corpuscular volume (um3), platelet count (103/mm3), white blood cell count (103/mm3), neutrophil count (103/mm3), and lymphocyte count (103/mm3) were examined. Mean values of each of these variables (except platelet count), adjusted for the effects of age and smoking state (current smoker or nonsmoker), were computed by a convariance method.8
Results

PART I: MORTALITY
A total of 614 DPMC employees who satisfied the cohort criteria contributed 7232 person-years to the SMR determinations. Black employees accounted for only 11% of the study cohort. The average age at entry into the cohort was 31 years and the average follow up was 15 years (range less than 1 to 42 years). Duration of employment in jobs with potential exposure to butadiene ranged from less than 1 to 20 years and averaged 7-6 years. One third of the cohort members were hired before 1970. Seventy three per cent of the cohort had had a minimum of five years in jobs with potential exposure to butadiene; more than half (59%) of them were hired since 1970. The remaining 27% (n = 163) of the cohort did not meet the five year potential exposure criterion, but one half of their total duration of employment was in jobs with potential exposure to butadiene (2-5 years average duration of employment and 17 years of potential exposure); 82% of this group was hired in 1970 or later. Table 1 shows the vital and employment status distribution of the cohort on 31 December 1989. Follow up was almost 100%. A total of 589 employees were still alive and 53% of the --cohort members were still working at the end of the study period. Twenty four deaths were identified and death certificates were obtained for all of the decedents. One half of the 24 deaths occurred in cohort members hired before 1949. The SMR for all causes combined was 52% lower than expected when compared with the local country rates (SMR 48, 95% confidence interval (95% CI = 31-72)). The mortality for all malignant neoplasms was also significantly lower (SMR 34, 95% CI = 9-87), based on four observed deaths. There were no deaths due to cancer of the lymphatic and haematopoietic tissue in the group (1 2 expected), and only two deaths from lung cancer (SMR 42, 95% CI = 5-15 1). There were eight deaths due to heart disease (SMR 51, 95% CI = 22-101). Mortality from non-malignant respiratory disease was 20% lower than expected (SMR 80, 95% CI = 10-290). Because of the small number of deaths from any specific cause, the statistical findings are unstable as illustrated by the wide range of 95% CIs. For type I error (a) = 0 05 and type II error (if) = 0-20, the study size and duration is sufficient to detect a fivefold excess in lymphohaematopoietic cancer if it were present.
PART II: MORBIDITY Table 2 presents the characteristics of the 438 butadiene employees for whom illness absence data were available compared with the 2703 employees with no employment in jobs with potential exposure to butadiene. Age at entry and duration of employment were similar for both groups. The butadiene cohort had an average of 9 1 years in jobs involving butadiene. It is noteworthy that the average duration of employment for the internal comparison group was 1-3 years longer than the butadiene cohort (20-6 years v 19-3 years). Table 3 summarises the SMbRs by cause of morbidity for the butadiene employees. Shell butadiene employees had rates equal to or lower than the rest of the DPMC population. In particular, absences due to cancers were especially low (SMbR 51; 95% CI = 22-100), as were those due to heart disease (SMbR 60; 95% CI = 36-95). All causes of morbidity combined in the butadiene group were also significantly lower than the comparison group (SMbR 85; 95% CI = 78-93). There was one observed illness absence and 0-8 expected due to a lymphohaematopoietic neoplasm in the butadiene group, a non- Hodgkin's lymphoma (ICD code 202). This man was hired in 1970 at DPMC and worked for a total of seven years in butadiene jobs from 1971-7 and between 1980-1. Most of this employee's work history at DPMC has been spent in jobs with no exposure to butadiene. He was diagnosed with lymphoma in 1989, and is still alive and an active employee at DPMC. Table 4 summarises the relative frequencies of certain cardiovascular risk factors in the two groups. No differences were statistically significant, but workers in the butadiene group were somewhat less likely to smoke or to have high blood pressure. On the other hand, these workers were somewhat more likely to be obese and to have a serum cholesterol over 200 mg/dl (5-18 mmol/l).
PART III: HAEMATOLOGICAL DATA Tables 5 and 6 provide frequency distribution and mean data, respectively, for the haematological variables studied. The figure Consistent with industrial practice in the United States, employee hiring practices at DPMC during the study period included a preplacement medical examination. No specific screening was provided for employment in butadiene job assignments within the plant. The extremely favourable mortality, for all causes and heart disease, of this cohort is probably due to a combination of factors such as the healthy worker effect, the relative absence of risks related to employment, and the beneficial effects of continuing employment.9-12 As over half of the cohort members were hired in 1970 or later with an average follow up of 12 years; they were relatively young. The average age at close of follow up was 46 years; 53% of the cohort members were still working. It has been shown that a strong healthy worker effect may exist under these cohort characteristics.9- '3 In the mortality analysis restricted to employees with definite opportunity for exposure to butadiene there were no deaths from leukaemia or other lymphohaematopoietic neoplasm. If the risks described in the casecontrol study of Santos-Burgoa et al'4 were present at DPMC, the number of deaths from lymphohaematopoietic cancer should be greater than five and the probability of observing no such deaths would be less than 0-05. Leukaemias"4 15 and lymphosarcomas'6 have been reported to be in excess in some subgroups of short term styrene-butadiene rubber and 1,3-butadiene monomer workers. It has, however, been noted that even in those studies, the longer term employees in the industry were not affected, which questions the relevance of such associations to exposure to butadiene. '6-'8 The small population size and small number of deaths in the DPMC butadiene group result in unstable rates as reflected by the wide confidence intervals; however no evidence of any association between exposures to butadiene and cancer is seen in this study. On the contrary, a very strong healthy worker effect is present. More importantly, the illness-absence experience and ongoing haematological test results also show no evidence for any adverse health effects as a result of exposure to butadiene at concentrations found at DPMC. For these two morbidity analyses, the internal comparison of employees at the same location was used. No potential bias is associated with the healthy worker effect in this type of -study design. In an earlier morbidity study, DPMC employees as a whole were found to have slightly higher morbidity than the entire Shell Manufacturing employee population.'9 By contrast, the butadiene employee group at DPMC shows rates equal to or lower than the rest of DPMC for any cause of morbidity. It is unlikely that the slightly lower overall smoking rates in the butadiene group account for the lower morbidity seen, but smoking has been shown to be a major contributing factor to morbidity in the Shell employee population.20
The haematological test results for the butadiene employees showed no significant differences from those for the rest of DPMC, and showed no evidence for any exposure related effects on the haematological system. This is similar to results reported by Checkoway et al,2' which showed no evidence of any butadiene related haematological abnormality. The study of Checkoway et al found no significant mean differences in a single subgroup of eight workers with higher exposure to butadiene.3
When the Shell subgroup of 36 employees with at least one year of employment in a butadiene shipping job, (jobs with the highest potential exposure to 1,3-butadiene) was compared with the rest of the butadiene cohort, no mean differences were found. The shipping subgroup was chosen because job duties and exposures are similar to the eight tank farm workers evaluated by Checkoway et al. 21 Our findings confirm the lack of exposure related haematological effects in a somewhat larger population than that studied by Checkoway et al.
The haematological results are especially pertinent to current employees at current exposure concentrations. Not even subtle variations in mean haematological variables were found. The importance of this finding is that without evidence for bone marrow injury from exposure, it is difficult to postulate an association between exposure and later leukaemia, should it develop. This is by contrast with the Pliofilm workers exposed to benzene who clearly showed early evidence of marrow depression. 22 The morbidity analysis, because it considered morbidity events between 1982 and 1991 is primarily a study of employees with potential exposures to butadiene after 1970. Such analyses are likely to be more pertinent to current exposure to butadiene in industry than exposures experienced by employees during the second world war. The one case of illness absence due to lymphoma in the DPMC butadiene cohort does not represent an excess, and occurred in an employee with only seven of his 23 years to date with Shell spent in jobs with potential for exposure to butadiene.
The butadiene group in this study excluded employees whose career at DPMC was predominantely spent in jobs with no potential for exposure to butadiene. Longer term employees, who accounted for 73% of the cohort, had to have worked five years in jobs with potential for exposure to butadiene. 
